161 related articles for article (PubMed ID: 35989151)
1. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
[TBL] [Abstract][Full Text] [Related]
2. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
3. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR
J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417
[TBL] [Abstract][Full Text] [Related]
4. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
6. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
7. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
8. Naloxone availability in independent community pharmacies in Georgia, 2019.
Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting.
Napoli K; Grant M; Remines J; Nadpara P; Goode JR
J Am Pharm Assoc (2003); 2021; 61(4S):S127-S134. PubMed ID: 33441280
[TBL] [Abstract][Full Text] [Related]
11. Pharmacist furnishing of naloxone in California: A follow-up analysis.
Puzantian T; Gasper JJ; Ramirez CM
J Am Pharm Assoc (2003); 2021; 61(5):e108-e112. PubMed ID: 34246575
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
13. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
Xu J; Mukherjee S
Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
[TBL] [Abstract][Full Text] [Related]
14. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
15. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
16. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
17. Point-of-sale Naloxone: Novel Community-based Research to Identify Naloxone Availability.
Olives T; Willhite LA; Lee SC; Evans DK; Jensen A; Regelman HT; McGillis ES
West J Emerg Med; 2020 Aug; 21(5):1188-1194. PubMed ID: 32970574
[TBL] [Abstract][Full Text] [Related]
18. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
19. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
20. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]